Projects

IrsiCaixa is involved in a hundred national and international research projects active each year, funded by both public and private entities.

Keywords

Research group

Researcher

From date

To date

Genomic epidemiology of SARS-CoV-2 in Catalonia: virologic surveillance and outbreak control

Project status

Ongoing

Start/End

2021

/

2023

Principal investigator

Marc Noguera i Julian

Participating entities

IrsiCaixa, IGTP

Strategic lines

Cancer

Emerging infectious diseases

Financing entity

Fundació "La Marató" de TV3
Eclipse Ts2R-FL Inverted Research Microscope

Project status

Ongoing

Start/End

2021

/

2024

Principal investigator

Christian Brander

Participating entities

IrsiCaixa

Financing entity

Dormeur Foundation, Vaduz
In vitro antiviral screening of compounds provided by Pharma Mar on Ebola virus entry and on the replication of HIV-1, Zika and SARS-CoV-2

Project status

Ongoing

Start/End

2021

/

2022

Principal investigator

Ester Ballana Guix

Nuria Izquierdo Useros

Participating entities

IrsiCaixa

Strategic lines

Cancer

Emerging infectious diseases

Financing entity

PharmaMar
Impact of HIV envelope function and antigenicity on elite control of HIV replication

Project status

Ongoing

Start/End

2021

/

2023

Principal investigator

Julià Blanco Arbués

Participating entities

IrsiCaixa AIDS Research Institute, ISCII, Institut de Recerca Germans Trias i Pujol

Strategic lines

Immunopathology

Financing entity

ISCIII
EU Research Scholars Program in HIV

Project status

Ongoing

Start/End

2021

/

2023

Principal investigator

Sara Morón López

Participating entities

IrsiCaixa

Strategic lines

Global infectious diseases

Financing entity

GILEAD
Discovery of novel inhibitors of HIV-1 RNA biogenesis based on the inhibition of the ribonucleoprotein RRE-Rev

Project status

Ongoing

Start/End

2021

/

2024

Principal investigator

Javier Martínez-Picado

External researchers

José Alcamí, Vicente Marchán

Participating entities

IrsiCaixa, ISCIII, University of Barcelona, Catholic University of Valencia

Strategic lines

Therapies and vaccines
Reversing Immune Dysfunction for HIV-1 eradication

Project status

Ongoing

Start/End

2021

/

2026

Principal investigator

Javier Martínez-Picado

Maria Salgado Bernal

Participating entities

IrsiCaixa, Emory University, University of Southern California, Scripps Research College

Strategic lines

Global infectious diseases

Financing entity

National Institutes of Health (NIH)
Impact of synonymous HIV-1 genome recoding on virus immune response and latency

Project status

Ongoing

Start/End

2020

/

2023

Participating entities

IrsiCaixa AIDS Research Institute

Strategic lines

Immunopathology

Financing entity

Spanish Ministry of Science and Innovation (PID2019-103955RB-100)
Elimination of the HIV latent reservoir by using novel anti-CD4 chimeric antigen receptor T cells

Project status

Ongoing

Start/End

2021

/

2024

Principal investigator

Maria Salgado Bernal

Participating entities

IrsiCaixa, Josep Carreras Leukaemia Research Institute

Strategic lines

Immunopathology

Financing entity

Spanish Ministry of Science and Innovation

Reference

PID2020-115931RA-I00
High-throughput synthetic biology platform for surveillance and therapeutics development against current and future SARS-Coronaviruses

Project status

Ongoing

Start/End

2021

/

2024

Principal investigator

Maria Salgado Bernal

External researchers

Rafael Sanjuan

Participating entities

IrsiCaixa, IBE (CSIC:UPF), UPF

Strategic lines

Cancer

Emerging infectious diseases

Financing entity

Fundació "La Marató" de TV3

This project explores a new strategy to eliminate the latent HIV reservoir using antiCD4-CAR CD8+ T cells. This approach mimics the allo-reactive effect of transplants but without their risks, specifically targeting infected CD4+ cells while preserving the rest of the immune system. Experiments in in vitro and in vivo models will help validate this strategy as a step toward a potential HIV cure.